{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:activin-signaling-inhibitors",
  "owner": "cardio",
  "kind": "drug",
  "slug": "activin-signaling-inhibitors",
  "name": "Activin signaling inhibitors",
  "aliases": [
    "Activin Signaling Inhibitor",
    "Activin Signaling Inhibitors"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Activin signaling inhibitors are medicines that block signals carried by activin and related growth factors. The US label of Winrevair (sotatercept) calls it an activin signaling inhibitor that binds activin A and other growth factors of the same family, and says this improves the balance between signals that drive and signals that hold back the growth of blood vessel cells. A narrative review published in November 2026 calls targeting BMP/activin signaling a major advance in pulmonary arterial hypertension, and says a treatment framework recognizes it as a fourth treatment pathway alongside endothelin, nitric oxide and prostacyclin. Sotatercept is the only medicine in this group so far, and it has its own page. This is the class page.",
  "summary_technical": "Class page. The name and aliases use the RxClass class names: the established pharmacologic class on US drug labels Activin Signaling Inhibitor (EPC, class N0000194100) and the mechanism-of-action class Activin Signaling Inhibitors (read 2026-11-19). RxClass lists sotatercept as the only member of the EPC class, so sotatercept is filed here on that evidence. MeSH has descriptors for activins and activin receptors, which are the target and not the medicine class, so no MeSH identifier is recorded. Sources: the Winrevair label (BLA761363, effective 2026-09-21), whose mechanism section describes the class action, and a 2026 narrative review (PMC13764490, Journal of Clinical Medicine, CC BY 4.0) that describes BMP/activin signaling as a treatment pathway in pulmonary arterial hypertension. The review attributes the four-pathway framework to the 7th World Symposium on Pulmonary Hypertension; that document was not read. No trial result, dose or instruction is recorded.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-19",
  "last_evidence_check": "2026-11-19",
  "next_review_due": "2027-05-19",
  "identifiers": [],
  "navigation": {
    "cardio": {
      "system": [
        "blood-vessels",
        "heart"
      ],
      "condition-area": [
        "coronary-and-vascular-disease"
      ]
    }
  },
  "payload": {
    "level": "class",
    "mechanism": "The Winrevair label says sotatercept-csrk is an activin signaling inhibitor that binds to activin A and other TGF-beta superfamily ligands, and improves the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation."
  },
  "content_digest": "a7cdcf47ac45192a1f23f1754b425e2bb8ccd478f304a0927a1ab30ee09828a8",
  "review": {
    "content_digest": "a7cdcf47ac45192a1f23f1754b425e2bb8ccd478f304a0927a1ab30ee09828a8",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "The Winrevair label lists pulmonary arterial hypertension as the indication of its one member",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:pulmonary-arterial-hypertension",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": [
      {
        "predicate": "subtype_of",
        "label": "Has subtype",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:sotatercept",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-2678930-2026-11-19",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[0].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ]
  },
  "page_path": "drugs/activin-signaling-inhibitors/",
  "context_path": "api/v1/context/cardio--activin-signaling-inhibitors.md"
}
